AstraZeneca has entered a $1.7 billion kidney disease drug discovery partnership with China-based CSPC Pharmaceutical Group, expanding their ongoing collaboration into renal therapeutics using siRNA-based drug discovery and AI-driven molecular design systems. The agreement, announced on July 3, 2026, aims